SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-022109
Filing Date
2020-02-03
Accepted
2020-02-03 06:15:10
Documents
14
Period of Report
2020-01-31
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d821524d8k.htm   iXBRL 8-K 27852
2 EX-99.1 d821524dex991.htm EX-99.1 3474
6 GRAPHIC g821524g0201111212281.jpg GRAPHIC 5519
  Complete submission text file 0001193125-20-022109.txt   163294

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20200131.xsd EX-101.SCH 3105
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20200131_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20200131_pre.xml EX-101.PRE 11431
12 EXTRACTED XBRL INSTANCE DOCUMENT d821524d8k_htm.xml XML 3372
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 20566883
SIC: 2834 Pharmaceutical Preparations